The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Cytometry versus morphology in the monitoring of AML
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of replacing morphology with flow cytometry for monitoring patients with acute myeloid leukemia (AML). While flow cytometry is highly sensitive and specific for detecting residual AML, it has limitations. Therefore, Dr Loghavi recommends using it in combination with morphology for optimal surveillance. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
